Atossa Therapeutics, Inc.

BMV:ATOS * Stock Report

Market Cap: Mex$3.6b

Atossa Therapeutics Past Earnings Performance

Past criteria checks 0/6

Atossa Therapeutics's earnings have been declining at an average annual rate of -13.7%, while the Biotechs industry saw earnings growing at 13% annually.

Key information

-13.7%

Earnings growth rate

56.1%

EPS growth rate

Biotechs Industry Growth12.9%
Revenue growth raten/a
Return on equity-32.3%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Atossa Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BMV:ATOS * Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-261317
31 Mar 240-301418
31 Dec 230-301417
30 Sep 230-301417
30 Jun 230-321417
31 Mar 230-281317
31 Dec 220-271315
30 Sep 220-241212
30 Jun 220-21129
31 Mar 220-22129
31 Dec 210-21119
30 Sep 210-281010
30 Jun 210-2699
31 Mar 210-2387
31 Dec 200-2287
30 Sep 200-1385
30 Jun 200-1385
31 Mar 200-16106
31 Dec 190-17117
30 Sep 190-17107
30 Jun 190-17106
31 Mar 190-2585
31 Dec 180-2374
30 Sep 180-2374
30 Jun 180-2273
31 Mar 180-1152
31 Dec 170-1152
30 Sep 170-1152
30 Jun 170-952
31 Mar 170-651
31 Dec 160-661
30 Sep 160-671
30 Jun 160-1092
31 Mar 160-12102
31 Dec 150-13102
30 Sep 150-13101
30 Jun 150-13101
31 Mar 150-1391
31 Dec 140-1291
30 Sep 140-1292
30 Jun 140-12101
31 Mar 140-11101
31 Dec 131-11101

Quality Earnings: ATOS * is currently unprofitable.

Growing Profit Margin: ATOS * is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ATOS * is unprofitable, and losses have increased over the past 5 years at a rate of 13.7% per year.

Accelerating Growth: Unable to compare ATOS *'s earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATOS * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6%).


Return on Equity

High ROE: ATOS * has a negative Return on Equity (-32.32%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies